Schering-Plough's Heart Drug Fast Tracked By FDA
Posted on: Friday, 21 April 2006, 06:00 CDT
The FDA has granted fast track designation for SCH 530348, Schering-Plough's investigational oral thrombin receptor antagonist currently in phase II clinical development for secondary prevention of cardiovascular morbidity and mortality outcomes in at-risk patients.
Fast Track designation allows FDA to expedite review of drugs and biologics for serious or life-threatening conditions which demonstrate the potential to address unmet medical needs.
An important feature of fast track designation is that it emphasizes the critical nature of close, early communication between the FDA and the sponsor company to improve the efficiency of product development.
Schering-Plough is investigating SCH 530348 for prevention of arterial thrombosis in patients with acute coronary syndrome and those with prior myocardial infarction or stroke, as well as in patients with existing peripheral arterial disease.
Thrombosis may result in partial or complete blockage of critical arteries. This process is the underlying mechanism of most acute vascular events, including acute coronary syndromes (ACS) such as myocardial infarction (MI), and ischemic stroke, which are the leading causes of death.
Source: Datamonitor
Related Articles
- Moses Taylor Hospital Selects Patient Care Technology Systems' Automatic Patient and Asset Tracking Solution for Emergency Department
- Lehigh Valley Hospital and Health Network Implements Automatic Patient and Asset Tracking Software From Patient Care Technology Systems in Perioperative Department
- AIDS Healthcare Foundation Calls on FDA to Fast Track Its Oversight of Drug Advertising
- FDA Grants Fast Track Designation for TargeGen TG100-115 Cardiovascular Compound
- FDA Grants Fast Track Status to MyVax(R) Personalized Immunotherapy for Follicular Non-Hodgkin's Lymphoma
- FDA Grants Fast Track Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for Prevention of Pulmonary Fungal Infections in At-Risk Patients; First Inhaled Anti-Fungal Therapy Under Development for Immunosuppressed Patients
- FDA Grants Fast Track Designation to Schering-Plough for Its Thrombin Receptor Antagonist SCH 530348
- Schering-Plough Reports FDA Grants Fast Track Designation to Oral HCV Protease Inhibitor SCH 503034
- AHF Urges FDA to Fast Track Approval of Rapid HIV Test Kits for Home Use
- FDA Grants Fast Track Designation for Phenoxodiol in Oral Dosage Form for Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds